Financial Counselors Inc. Has $295,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

Financial Counselors Inc. lowered its position in Edwards Lifesciences Co. (NYSE:EW) by 7.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,476 shares of the medical research company’s stock after selling 384 shares during the period. Financial Counselors Inc.’s holdings in Edwards Lifesciences were worth $295,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. First Community Trust NA bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $29,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences in the third quarter worth $32,000. Avior Wealth Management LLC raised its holdings in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after acquiring an additional 308 shares during the period. Webster Bank N. A. acquired a new position in Edwards Lifesciences during the 2nd quarter worth $39,000. Finally, Peoples Bank KS bought a new stake in Edwards Lifesciences during the third quarter valued at about $40,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 1.0 %

EW stock opened at $71.35 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market capitalization of $42.08 billion, a price-to-earnings ratio of 10.30, a P/E/G ratio of 4.05 and a beta of 1.12. The business has a fifty day moving average price of $68.10 and a 200 day moving average price of $75.15. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the business posted $0.59 earnings per share. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. Analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. This trade represents a 9.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,000 shares of company stock valued at $2,657,000. 1.29% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

EW has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Citigroup reduced their price objective on Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a research report on Tuesday, October 1st. Morgan Stanley reaffirmed an “equal weight” rating and set a $70.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 11th. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, UBS Group dropped their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a report on Tuesday, September 10th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $76.85.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.